$99.49
Insmed
Performance
Dividends
1W
1M
YTD
1Y
3Y
20/36
Growth
Score
7/36
Dividend
Score
Valuation
PE Ratio
-17.76
PS Ratio
49.6
RSI
-
3
PEG Ratio
0.28
3
PRG Ratio
0.06
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
104.03%
3
Gross Margin
76.16%
3
Current Ratio
5.86
Return on Assets
-56.21%
Return on Equity
-446.98%
Return on inv. Capital
-56.09%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 363.71M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -913.77M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 277.96M
2018
2019
2020
2021
2022
2023
2024
6
Events
INSM
Insmed
in 283 days
before market open
Earnings per Share is expected with - and revenue with - .
INSM
Insmed
in 206 days
before market open
Earnings per Share is expected with - and revenue with - .
INSM
Insmed
in 94 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Pharmaceuticals
IPO Date
01.06.2000
MaketCap
18.90B
Country
US
CEO
William H. Lewis
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Updated 29.06.2025